Kevin Ho, MBA, MPH, is a member of the corporate development team at Gilead Sciences, where he investigates drug development programs in autoimmune disease, oncology, and virology for potential partnering or M&A purposes. Previously, he worked in portfolio management at Genentech, in vaccine market access at the Clinton Health Access Initiative, and on the Health and Life Sciences team at Gates Ventures. Kevin is passionate about innovation in the life sciences – for the sake of scientific progress, human health, and economic development. He is fascinated by the innovation that can occur in economic clusters, and hopes to enable translational science beyond the geographies where it currently occurs. Kevin attended Yale University, where he earned a BA and Master’s degree in Health Policy, and Stanford University, where he earned an MBA.